In accordance with the previous reports [17], our analysis of the pGI-DLBCL exome confirmed the high prevalence of mutations in the cell cycle and apoptosis regulatory pathway, with potential tumor driver mutations in TP53 (22/53), CCND3 (9/53) and MYC (8/53) in over 60% patients. The gene discussed is TP53; the disease is neoplasm.